Work

Moving Toward a Consensus

Year: 2024

Type: editorial

Abstract: ypertension is a primary modifiable risk factor for coronary artery disease (CAD), heart failure, stroke, and chronic kidney disease (CKD). 1 The 2017 American College of Cardiology/American Heart Association (ACC/AHA) Guidelines for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults and the recently published 2023 European Society of Hypertension (ESH) guidelines for the management of arterial hypertension are two primary sources on best practices for hypertension diagnosis and treatment.2,3 This analysis reviews major updates in the 2023 ESH BP guideline and highlights key similarities and differences with the 2017 ACC/AHA blood pressure (BP) guideline.Compared to the 2018 European Society of Cardiology/ESH BP guideline, changes in the 2023 ESH guideline were relatively minor.4 Importantly, the 2023 ESH guideline is more concordant with the 2017 ACC/AHA guideline in several key respects (Figure 1).Both guidelines emphasize the use of standardized measurement protocols to ensure the accuracy of BP measurements.This includes utilizing validated, cuffed devices to obtain office BP measurements across multiple clinic visits.The ESH guideline recommends against the use of cuffless devices, expressing concerns about reliance of cuffless devices on incompletely validated predictive technologies to estimate BP, absence of standardized validation

Source: JACC Advances

DOI: 10.1016/j.jacadv.2024.101230

Authors: Prasantha L. Vemu, Eugene Yang, Joseph E. Ebinger

Institutions: University of Washington, Cedars-Sinai Medical Center, Cedars-Sinai Smidt Heart Institute

Language: English

Topic: Blood Pressure and Hypertension Studies

Subfield: Cardiology and Cardiovascular Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,850